{"id":"W4410424571","doi":"10.1016/j.esmoop.2025.105051","title":"First-in-human study of FAZ053, an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody, alone and in combination with spartalizumab (anti-PD-1), in patients with advanced malignancies","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Chugai Pharmaceutical; Genentech; Ipsen; Servier; Astellas Pharma; Eisai; Daiichi-Sankyo; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; Les Laboratories Pierre Fabre; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Monoclonal antibody; Medicine; Antibody; Programmed cell death 1; Monoclonal; Cancer research; PD-L1; Oncology; Immunology; Immunotherapy; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002225382,0.001757793,0.001937365,0.0004590394,0.0006458363,0.001459577,0.0008719225,0.001257006,0.002745911],"category_scores_gemma":[0.001184168,0.0008258731,0.001673666,0.0004153158,0.001682179,0.001209822,0.000401535,0.004009585,0.0008668797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001631485,"about_ca_system_score_gemma":0.001727188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001272568,"about_ca_topic_score_gemma":0.002560915,"domain_scores_codex":[0.9992813,0.000330212,0.00003531319,0.0001434019,0.00006786721,0.0001419566],"domain_scores_gemma":[0.998893,0.0001771036,0.000238367,0.0001374291,0.00006270537,0.0004913259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5652537,0.1935025,0.016127,0.0008001221,0.003179873,0.0006756157,0.0007595557,0.003485053,0.08830072,0.0005098424,0.005830977,0.121575],"study_design_scores_gemma":[0.2183045,0.7535455,0.01331977,0.00002477177,0.0007491811,0.0004312385,0.00007300924,0.001042291,0.008308959,0.0002037856,0.003960521,0.00003641229],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929821,0.002086504,0.0009817621,0.0003033264,0.0001171677,0.00123728,0.0009629053,0.0001088904,0.001220041],"genre_scores_gemma":[0.9934276,0.001081536,0.001389396,0.0004661786,0.0001647194,0.0007431925,0.001102319,0.00002927266,0.001595828],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002745911,"threshold_uncertainty_score":0.0118373,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01480101674882538,"score_gpt":0.3076671963837465,"score_spread":0.2928661796349211,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}